Cell-permeable peptide inhibitors of JNK. Novel blockers of β-cell death
Diabetes, ISSN: 0012-1797, Vol: 50, Issue: 1, Page: 77-82
2001
- 540Citations
- 166Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations540
- Citation Indexes536
- 536
- CrossRef484
- Patent Family Citations4
- Patent Families4
- Captures166
- Readers166
- 108
- 58
- Mentions2
- References2
- Wikipedia2
Article Description
Stress conditions and proinflammatory cytokines activate the c-Jun NH-terminal kinase (JNK), a member of the stress-activated group of mitogen-activated protein kinases (MAPKs). We recently demonstrated that inhibition of JNK signaling with the use of the islet-brain (IB) 1 and 2 proteins prevented interleukin (IL)-1β-induced pancreatic β-cell death. Bioactive cell-permeable peptide inhibitors of JNK were engineered by linking the minimal 20-amino acid inhibitory domains of the IB proteins to the 10-amino acid HIV-TAT sequence that rapidly translocates inside cells. Kinase assays indicate that the inhibitors block activation of the transcription factor c-Jun by JNK. Addition of the peptides to the insulin-secreting βTC-3 cell line results in a marked inhibition of IL-1β-induced c-jun and c-fos expression. The peptides protect βTC-3 cells against apoptosis induced by IL-1β. A11-D retro-inverso peptides penetrate cells as efficiently as the L-enantiomers, decrease c-Jun activation by JNK, and remain highly stable inside cells. These latter peptides confer full protection against IL-1β-induced apoptosis for up to 2 weeks of continual treatment with IL-1β. These data establish these bioactive cell-permeable peptides as potent pharmacological compounds that decrease intracellular JNK signaling and confer long-term protection to pancreatic β-cells from IL-1β-induced apoptosis.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0035152487&origin=inward; http://dx.doi.org/10.2337/diabetes.50.1.77; http://www.ncbi.nlm.nih.gov/pubmed/11147798; https://diabetesjournals.org/diabetes/article/50/1/77/10881/Cell-Permeable-Peptide-Inhibitors-of-JNKNovel; https://dx.doi.org/10.2337/diabetes.50.1.77; https://diabetes.diabetesjournals.org/content/50/1/77
American Diabetes Association
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know